Security key
00166B105
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 45,776,694
- Total 13F value
- $510,423,087
- Share change
- +11,935
- Put/Call ratio
- 15%
- SEC-reported price per share
- $11.15
- Number of holders
- 105
- Value change
- -$5,822,832
- Number of buys
- 49
- Number of sells
- 42
- Shares outstanding
- 133,751,136
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
105
Top holders
10
ALXO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2024
Previous quarter: Q4 2023
ALX ONCOLOGY HOLDINGS INC SEC filings
ALX ONCOLOGY HOLDINGS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00166B105
Recent filing periods:
Ownership snapshot
Top reported holders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
venBio Partners LLC
Disclosed value leader
venBio Partners LLC
Comparable rows
15/15
Latest evidence
31 Dec 2023
13F
Lead comparable stake: 7.3%
Showing 1-6 of 15 holder rows.
Quick read
venBio Partners LLC leads the comparable SEC ownership view at 7.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens venBio Partners LLC's linked filing trail.
Comparable ownership
Top 5
venBio Partners LLC
7.3%
FMR LLC
5.6%
Vivo Capital, LLC
3.2%
Redmile Group, LLC
2.7%
Cormorant Asset Management, LP
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| venBio Partners LLC |
13F
Company
|
7.3%
|
$144,431,883
9,699,925 shares
|
— | 31 Dec 2023 |
| FMR LLC |
13F
Company
|
5.6%
|
$111,270,305
7,472,821 shares
|
— | 31 Dec 2023 |
| Vivo Capital, LLC |
13F
Company
|
3.2%
|
$62,836,515
4,220,048 shares
|
— | 31 Dec 2023 |
| Redmile Group, LLC |
13F
Company
|
2.7%
|
$54,486,441
3,659,264 shares
|
— | 31 Dec 2023 |
| Cormorant Asset Management, LP |
13F
Company
|
2.3%
|
$46,785,556
3,142,079 shares
|
— | 31 Dec 2023 |
| ORBIMED ADVISORS LLC |
13F
Company
|
2.3%
|
$46,084,550
3,095,000 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
105
Shares
45,776,694
Rows available
105
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q4 2023 Across Filers
Q4 2023 holders
93
Q1 2024 holders
105
Holder diff
12
| Investor | Q4 2023 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q4 2023 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend